“In 2019 Biogen demonstrated strong execution across all of our core business areas with resilience in MS, continued strong worldwide growth for Spinraza, and an expanded biosimilars business,” noted Michel Vounatsos, Biogen’s chief executive officer.
January 30, 2020
· 2 min read
·